Ganirelix

  • Check with publisher
  • Published date: April 25, 2019
    • Shirley, New York, United States

Ganirelix acetate is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-napthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N 9 ,N 10 -diethyl- D-homoarginyl-L-leucyl-N 9 ,N 10 -diethyl-L-homoarginyl-L-prolyl-D-alanylamide acetate. https://www.creative-diagnostics.com/Ganirelix-124481-427.htm

Result 0 votes
Thomas Schmitt
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Native Gluconobacter industrius D-Fructose Dehydrogenase

    Native Gluconobacter industrius D-Fructose Dehydrogenase

    Life Sciences New York (New York) August 13, 2020 Check with publisher

    37250-85-4 D-fructose dehydrogenase is a heterotrimeric membrane-bound enzyme commonly seen in various Gluconobacter sp. especially in Gluconobacter japonicus (Gluconobacter industrius). It has a molecular mass of ca. 140 kDa, consisting of subunits ...

  • Data Integrity: FDA/EU Requirements and Implementation

    Data Integrity: FDA/EU Requirements and Implementation

    Life Sciences (Copenhagen) April 28, 2020 Check with publisher

    This 2-day course explains the background to the data integrity regulations and sets out the expectations of pharmaceutical regulators. All the current data integrity guidances emphasise a risk-based approach to compliance, and the course explains ho...

  • 5th Annual ComplianceOnline Medical Device Summit 2020

    5th Annual ComplianceOnline Medical Device Summit 2020

    Life Sciences Massachusetts (Boston) February 12, 2020 Check with publisher

    ComplianceOnline Medical Device Summit 2020 brings together Speakers and executives from FDA/CDRH, Ex-FDA Officials and Renowned R&D experts and technology innovators to share information regarding opportunities, obstacles, best practices and cha...